Mechanisms underlying the hepatotoxicity of nonsteroidal antiinflammatory drugs

Drug-Induced Liver Disease

Volumn , Issue , 2013, Pages 343-367

  Boelsterli, Urs A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Diclofenac; Hepatotoxicity; Idiosyncratic drug induced liver injury; Mechanisms; Mitochondria; Nimesulide; Nonsteroidal antiinflammatory drugs; Sulindac

Indexed keywords

EID: 84882649354     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387817-5.00021-2     Document Type: Chapter

References (195)

1. Aithal G.P., Day C.P. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007, 11:563-575.
2. Lewis J.H. Nonsteroidal anti-inflammatory drugs and leukotriene receptor antagonists: pathology and clinical presentation of hepatotoxicity. Drug-induced liver disease 2007, 439-464. Informa Health Care, New York. 2nd ed. N. Kaplowitz, L. DeLeve (Eds.).
3. Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage?. World J Gastroenterol 2010, 16:5651-5661.
4. Aithal G.P. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 2011, 7:139-150.
5. Boelsterli U.A., Kashimshetty R. Idiosyncratic drug-induced liver injury: mechanisms and susceptibility factors. Hepatic toxicology 2010, vol. 9:383-402. Elsevier, Oxford, UK. 2nd ed.
6. Chen M., Vijay V., Shi Q., Liu Z., Fang H., Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 2011, 16:697-703.
7. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guilleminet C., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
8. Needleman P., Isakson P.C. The discovery and function of COX-2. J Rheumatol 1997, 24:6-8.
9. Pessayre D., Mazel P., Descatoire V., Rogier E., Feldmann G., Benhamou J.P. Inhibition of hepatic drug-metabolizing enzymes by arachidonic acid. Xenobiotica 1979, 9:301-310.
10. Gasperini R., Leone R., Velo G.P., Fracasso M.E. The inhibition of hepatic microsomal drug metabolism in rats by non-steroidal anti-inflammatory drugs. Pharmacol Res 1990, 22(Suppl. 3):115-116.
11. Hagmann W., Kirn A., Keppler D. Role of leukotrienes in acute inflammatory liver disease. Modulation of liver cell expression 1987, 423-433. MTP Press, Lancaster. W. Reutter, P.C. Heinrich, H. Popper, D. Keppler, I.M. Arias, L. Landmann (Eds.).
12. Trudell J.R., Gut J., Costa A.K. Leukotrienes in hepatocyte injury. Modulation of liver cell expression 1987, 411-421. MTP Press, Lancaster. W. Reutter, P.C. Heinrich, H. Popper, D. Keppler, I.M. Arias, L. Landmann (Eds.).
13. Reilly T.P., Brady J.N., Marchik M.R., Bourdi M., George J.W., Radonovich M.F., et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001, 14:1620-1628.
14. Paulus H.E. FDA Arthritis Advisory Committee meeting. Arthritis Rheum 1982, 25:1124-1125.
15. Agundez J.A.G., Lucena M.I., Martinez C., Andrade R.J., Blanca M., Ayuso P., et al. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2011, 7:817-828.
16. Borga O., Borga B. Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study. J Pharmacokinet Biopharm 1997, 25:63-77.
17. Vree T.B., Van den Biggelaar-Martea M., Verwey-Van Wissen C.P.W.G.M., Vree M.L., Guelen P.J.M. The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acylglucuronides in humans. Effect of cimetidine. Br J Clin Pharmacol 1993, 35:467-472.
18. Siraki A.G., Chevaldina T., O'Brien P.J. Application of quantitative structure-toxicity relationships for acute NSAID cytotoxicity in rat hepatocytes. Chem-Biol Interact 2005, 151:177-191.
19. Jurima-Romet M., Crawford K., Huang H.S. Comparative cytotoxicity of non-steroidal anti-inflammatory drugs in primary cultures of rat hepatocytes. Toxicol in Vitro 1994, 8:55-66.
20. Li Y., Slatter J.G., Zhang Z., Li Y., Doss G.A., Braun M.P., et al. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab Disp 2008, 36:469-473.
21. Li F., Chordia M.D., Huang T.T., Macdonald T.L. In vitro nimesulide studies toward understanding idiosyncratic hepatotoxicity: Diiminoquinone formation and conjugation. Chem Res Toxicol 2009, 22:72-80.
22. Kale V.M., Hsiao C.J., Boelsterli U.A. Nimesulide-induced electrophile stress activates Nrf2 in human hepatocytes and mice but is not sufficient to induce hepatotoxicity in Nrf2-deficient mice. Chem Res Toxicol 2010, 23:967-976.
23. Sorensen E.M.B., Acosta D. Relative toxicities of several nonsteroidal antiinflammatory compounds in primary cultures of rat hepatocytes. J Toxicol Environ Health 1985, 16:425-440.
24. Miners J.O., Birkett D.J. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998, 45:525-538.
25. Zhou S.F., Zhou Z.W., Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010, 278:165-188.
26. Koukouritaki S.B., Manro J.R., Marsh S.A., Stevens J.C., Rettie A.E., McCarver D.G., et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004, 308:965-974.
27. Shen S., Marchick M.R., Davis M.R., Doss G.A., Pohl L.R. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem Res Toxicol 1999, 12:214-222.
28. Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab 2003, 4:319-329.
29. Miyamoto G., Zahid N., Uetrecht J.P. Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem Res Toxicol 1997, 10:414-419.
30. Tang W., Stearns R.A., Bandiera S.M., Zhang Y., Raab C., Braun M.P., et al. Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos 1999, 27:365-372.
31. Tang W., Stearns R.A., Wang R.W., Chiu S.H.L., Baillie T.A. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 1999, 12:192-199.
32. Yan Z., Li J.L., Huebert N., Caldwell G.W., Du Y., Zhong H. Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides. Drug Metab Dispos 2005, 33:706-713.
33. Shen S.J., Hargus S.J., Martin B.M., Pohl L.R. Cytochrome P4502C11 is a target of diclofenac covalent binding in rats. Chem Res Toxicol 1997, 10:420-423.
34. Kang P., Dalvie D., Smith E., Renner M. Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts. Chem Res Toxicol 2009, 22:106-117.
35. Tafazoli S., O'Brien P.J. Peroxidases: a role in the metabolism and side effects of drugs. Drug Disc Today 2005, 10:617-625.
36. Galati G., Tafazoli S., Sabzevari O., Chan T.S., O'Brien P.J. Idiosyncratic NSAID drug induced oxidative stress. Chem-Biol Interact 2002, 142:25-41.
37. O'Brien P.J. Peroxidases. Chem-Biol Interact 2000, 129:113-139.
38. Yang M., Chordia M.D., Li F., Huang T., Linden J., Macdonald T.L. Neutrophil- and myeloperoxidase-mediated metabolism of reduced nimesulide: evidence for bioactivation. Chem Res Toxicol 2010, 23:1691-1700.
39. Etienne F., Resnick L., Sagher D., Brot N., Weissbach H. Reduction of sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxidase reductase system. Biochem Biophys Res Commun 2003, 312:1005-1010.
40. Leite S., Martins N.M., Dorta D.J., Curti C., Uyemura S.A., dos Santos A.C. Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide. Basic Clin Pharmacol Toxicol 2006, 99:294-299.
41. Sevoz C., Benoit E., Buronfosse T. Thioesterification of 2-arylpropionic acids by recombinant acyl-coenzyme A synthetases (ACS1 and ACS2). Drug Metab Dispos 2000, 28:398-402.
42. Hall S.D., Qian X.T. The role of coenzyme A in the biotransformation of 2-arylpropionic acids. Chem-Biol Interact 1994, 90:235-251.
43. Mayer J.M., Testa B., Roy-de Vos M., Audergon C., Etter J.C. Interactions between the in vitro metabolism of xenobiotics and fatty acids. The case of ibuprofen and other chiral profens. Arch Toxicol 1995, Suppl. 17:499-513.
44. Caldwell J., Marsh M.V. Interrelationships between xenobiotic metabolism and lipid biosynthesis. Biochem Pharmacol 1983, 32:1667-1672.
45. Mayer J.M., Roy de Vos M., Audergon C., Testa B., Etter J.C. Interactions of anti-inflammatory 2-arylpropionates (profens) with the metabolism of fatty acids: in vitro studies. Int J Tissue React 1994, 16:59-72.
46. Sallustio B.C., Nunthasomboon S., Drogemuller C.J., Knights K.M. In vitro covalent binding of nafenopin-CoA to human liver proteins. Toxicol Appl Pharmacol 2000, 163:176-182.
47. Hayball P.J. Chirality and nonsteroidal anti-inflammatory drugs. Drugs 1996, 52:47-58.
48. Li C., Grillo M.P., Benet L.Z. In vivo mechanistic studies on the metabolic activation of 2-phenylpropionic acid in rat. J Pharmacol Exp Ther 2003, 305:250-256.
49. Mackenzie P.I., Owens I.S., Burchell B., Bock K.W., Bairoch A., Bélanger A., et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997, 7:255-269.
50. Jin C., Miners J.O., Lillywhite K.J., Mackenzie P.I. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 1993, 264:475-479.
51. Burchell B., McGurk K., Brierley C.H., Clarke D.J. UDP-glucuronosyltransferases. Comprehensive toxicology 1997, Vol. 3:401-435. Elsevier, New York.
52. Kuehl G.E., Lampe J.W., Potter J.D., Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005, 33:1027-1035.
53. Kretz-Rommel A., Boelsterli U. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to acute cell injury in cultured rat hepatocytes. Toxicol Appl Pharmacol 1993, 120:155-161.
54. Koga T., Fujiwara R., Nakajima M., Yokoi T. Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. Drug Metab Dispos 2011, 39:54-60.
55. Le H.T., Franklin M.R. Selective induction of phase II drug metabolizing enzyme activities by quinolines and isoquinolines. Chem Biol Interact 1997, 103:167-178.
56. Patel M., Tang B.K., Grant D.M., Kalow W. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics 1995, 5:287-297.
57. Coffman B.L., King C.D., Rios G.R., Tephly T.R. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7(268). Drug Metab Dispos 1998, 26:73-77.
58. Daly A.K., Aithal G.P., Leathart J.B.S., Swainsbury R.A., Dang T.S., Day C.P. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterol 2007, 132:272-281.
59. Kirkman S.K., Zhang M.Y., Horwatt P.M., Scatina J. Isolation and identification of bromfenac glucoside from rat bile. Drug Metab Dispos 1998, 26:720-723.
60. Fontana R.J., McCashland T.M., Brenner K.G., Appelman H.D., Gunartanam N.T., Wisecarver J.L., et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. Liver Transplant Surg 1999, 5:480-484.
61. Moses P.L., Schroeder B., Alkhatib O., Ferrentino N., Suppan T., Lidofsky S.D. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999, 94:1393-1396.
62. Skjodt N.M., Davies N.M. Clinical pharmacokinetics and pharmacodynamics of bromfenac. Clin Pharmacokinet 1999, 36:399-408.
63. Grillo M.P., Knutson C.G., Sanders P.E., Waldon D.J., Hua F., Ware J.A. Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab Dispos 2003, 31:1327-1336.
64. Grillo M.P., Hua F., Knutson C.G., Ware J.A., Li C. Mechanistic studies on the bioactivation of diclofenac: identification of diclofenac-S-acyl-glutathione in vitro in incubations with rat and human hepatocytes. Chem Res Toxicol 2003, 16:1410-1417.
65. Grillo M.P. Drug S-acyl glutathione thioesters: chemical synthesis, bioanalytical properties, chemical reactivity, and biological formation and degradation. Curr Drug Metab 2011, 12:229-244.
66. Watt J.A., King A.R., Dickinson R.G. Contrasting systemic stabilities of the acyl and phenolic glucuronides of diflunisal in the rat. Xenobiotica 1991, 21:403-415.
67. Georges H., Presle N., Buronfosse T., Fournel-Gigleux, Netter P., Magdalou J., et al. In vitro stereoselective degradation of carprofen glucuronide by human serum albumin. Characterization of sites and reactive amino acids. Chirality 2000, 12:53-62.
68. Hayball P.J. Formation and reactivity of acyl glucuronides: the influence of chirality. Chirality 1995, 7:1-9.
69. Lagas J.S., van der Kruijssen C.M.M., van de Wetering K., Beijnen J.H., Schinkel A.H. Transport of diclofenac by BCRP (ABCG2) and stimulation of MRP2-(ABCC2-)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Disp 2008, 37:129-136.
70. Iwaki M., Bischer A., Nguyen A.C., Mcdonagh A.F., Benet L.Z. Stereoselective disposition of naproxen glucuronide in the rat. Drug Metab Dispos 1995, 23:1099-1103.
71. Seitz S., Kretz-Rommel A., Oude Elferink R.P.J., Boelsterli U.A. Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 1998, 11:513-519.
72. Lagas J.S., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 2010, 77:687-694.
73. Kauffmann H.M., Keppler D., Gant T.W., Schrenk D. Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch Toxicol 1998, 72:763-768.
74. Rost D., Kartenbeck J., Keppler D. Changes in the localization of the rat canalicular conjugate export pump Mrp2 in phalloidin-induced cholestasis. Hepatology 1999, 29:814-821.
75. Paulusma C.C., Bosma P.J., Zaman G.J.R., Bakker C.T.M., Otter M., Scheffer G.L., et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996, 271:1126-1128.
76. Wang M., Dickinson R.G. Bile duct ligation promotes covalent drug-protein adduct formation in plasma but not in liver of rats given zomepirac. Life Sci 2000, 68:525-537.
77. Yesair D.W., Callahan M., Remington L., Kensler C.J. Role of the entero-hepatic cycle of indomethacin on its metabolism, distribution in tissues and its excretion by rats, dogs and monkeys. Biochem Pharmacol 1970, 19:1579-1590.
78. Brune K. Is there a rational basis for the different spectra of adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs)?. Drugs 1990, 40(Supp1.5):12-15.
79. Reuter B.K., Davies N.M., Wallace J.L. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997, 112:109-117.
80. Seitz S., Boelsterli U.A. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 1998, 115:1476-1482.
81. Dobrinska M.R., Furst D.E., Spiegel T., Vincek W.C., Tompkins R., Duggan D.E., et al. Biliary secretion of sulindac and metabolites in man. Biopharm Drug Dispos 1983, 4:347-358.
82. Bolder U., Trang N.V., Hagey L.R., Schteingart C.D., Ton-Nu H.T., Cerrè C., et al. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 1999, 117:962-971.
83. Smith P.C., McDonagh A.F., Benet L.Z. Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J Clin Invest 1986, 77:934-939.
84. Foxworthy P.S., Perry D.N., Eacho P.I. Induction of peroxisomal β-oxidation by nonsteroidal anti-inflammatory drugs. Toxicol Appl Pharmacol 1993, 118:271-274.
85. Vidal-Puig A.J., Considine R.V., Jimenez-Liñan M., Werman A., Pories W.J., Caro J.F., et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997, 99:2416-2422.
86. y mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001, 35:17-23.
87. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272:3406-3410.
88. Rahman M.A., Dhar D.K., Masunaga R., Yamanoi A., Kohno H., Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 2000, 60:2085-2089.
89. Shiff S.J., Qiao L., Tsai L., Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995, 96:491-503.
90. Hanif R., Pittas A., Feng Y., Koutsos M.I., Qiao L., Staianocoico L., et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996, 52:237-245.
91. Shiff S.J., Koutsos M.I., Qiao L., Rigas B. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996, 222:179-188.
92. Zhu G.H., Wong B.C.Y., Ching C.K., Lai K.C., Lam S.K. Differential apoptosis by indomethacin in gastric epithelial cells through the constitutive expression of wild-type p53 and/or upregulation of c-myc. Biochem Pharmacol 1999, 58:193-200.
93. Liou J.Y., Wu C.C., Chen B.R., Yen L.B., Wu K.K. Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptorδ transcriptional pathway. Molec Pharmacol 2008, 74:1399-1406.
94. McDougall P., Markham A., Cameron I., Sweetman A.J. The mechanism of inhibition of mitochondrial oxidative phosphorylation by the non-steroidal anti-inflammatory agent diflunisal. Biochem Pharmacol 1983, 32:2595-2598.
95. Mahmud T., Scott D.L., Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996, 55:211-213.
96. Petrescu I., Tarba C. Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat. Biochim Biophys Acta (Bioenergetics) 1997, 1318:385-394.
97. Browne G.S., Nelson C., Nguyen T., Ellis B.A., Day R.O., Williams K.M. Stereoselective and substrate-dependent inhibition of hepatic mitochondrial β-oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen, and ketorolac. Biochem Pharmacol 1999, 57:837-844.
98. Moreno-Sanchez R., Bravo C., Vasquez C., Ayala G., Silveira L.H., Martinez-Lavin M. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs. Biochem Pharmacol 1999, 57:743-752.
99. Tokomitsu Y., Lee S., Ui M. In vitro effects of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation in rat liver mitochondria. Biochem Pharmacol 1977, 26:2101-2106.
100. Knights K.M., Drew R. The effects of ibuprofen enantiomers on hepatocyte intermediary metabolism and mitochondrial respiration. Biochem Pharmacol 1992, 44:1291-1296.
101. Masubuchi Y., Saito H., Horie T. Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated rat hepatocytes. J Pharmacol Exp Ther 1998, 287:208-213.
102. Ponsoda X., Bort R., Jover R., Gomezlechon M.J., Castell J.V. Molecular mechanism of diclofenac hepatotoxicity: association of cell injury with oxidative metabolism and decrease in ATP levels. Toxicol in Vitro 1995, 9:439-444.
103. Masubuchi Y., Yamada S., Horie T. Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 2000, 292:982-987.
104. Daouphars M., Koufany M., Benani A., Marchal S., Merlin J.L., Netter P., et al. Uncoupling of oxidative phosphorylation and Smac/DIABLO release are not sufficient to account for induction of apoptosis by sulindac sulfide in human colorectal cancer cells. Int J Oncol 2005, 26:1069-1077.
105. Monteiro J.P., Martins A.F., Lucio M., Reis S., Pinheiro T.J.T., Geraldes C.F., et al. Nimesulide interaction with membrane model systems: Are membrane physical effects involved in nimesulide mitochondrial toxicity?. Toxicol in Vitro 2011, 25:1215-1223.
106. Chung H., Kim H.J., Jang K.S., Kim M., Yang J., Kim J.H., et al. Comprehensive analysis of differential gene expression profiles on diclofenac-induced acute mouse liver injury and recovery. Toxicol Lett 2006, 166:77-87.
107. Tay V.K.S., Wang A.S., Leow K.Y., Ong M.M.K., Wong K.P., Boelsterli U.A. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic Biol Med 2005, 39:949-959.
108. Gomez-Lechon M.J., Ponsoda X., O'Connor E., Donato T., Castell J.V., Jover R. Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS. Biochem Pharmacol 2003, 66:2155-2167.
109. Inoue A., Muranaka S., Fujita H., Kanno T., Tamai H., Utsumi K. Molecular mechanisms of diclofenac-induced apoptosis of promyelocytic leukemia: dependency on reactive oxygen species, Akt, Bid, cytochrome c, and caspase pathway. Free Radic Biol Med 2004, 37:1290-1299.
110. Lim M.S., Lim P.L.K., Gupta R., Boelsterli U.A. Critical role of free cytosolic calcium, but not uncoupling, in mitochondrial permeability transition and cell death induced by diclofenac oxidative metabolites in immortalized human hepatocytes. Toxicol Appl Pharmacol 2006, 217:322-331.
111. van Leeuwen J.S., Orij R., Luttik M.A.H., Smits G.J., Vermeulen N.P.E., Vos J.C. Subunits Rip1p and Cox9p of the respiratory chain contribute to diclofenac-induced mitochondrial dysfunction. Microbiology 2011, 157:685-694.
112. Nadanaciva S., Bernal A., Aggeler R., Capaldi R.A., Will Y. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol in Vitro 2007, 21:902-911.
113. Baines C.P. The molecular composition of the mitochondrial permeability transition pore. J Mol Cell Cardiol 2009, 46:850-857.
114. Palmeira C.M., Rana M.I., Frederick C.B., Wallace K.B. Induction of the mitochondrial permeability transition in vitro by short-chain carboxylic acids. Biochem Biophys Res Commun 2000, 272:431-435.
115. Uyemura S.A., Santos A.C., Mingatto F.E., Jordani M.C., Curti C. Diclofenac sodium and mefenamic acid: potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch Biochem Biophys 1997, 342:231-235.
116. Al-Nasser I.A. Ibuprofen-induced liver mitochondrial permeability transition. Toxicol Lett 2000, 111:213-218.
117. Masubuchi Y., Nakayama S., Horie T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 2002, 35:544-551.
118. Suzuki Y., Inoue T., Ra C. NSAIDs, mitochondria and calcium signaling: special focus on aspirin/salicylates. Pharmaceuticals 2010, 3:1594-1613.
119. Dara L., Ji C., Kaplowitz N. The contribution of endoplasmic reticulum stress to liver diseases. Hepatology 2011, 53:1752-1763.
120. Wang X., Thomas B., Sachdeva R., Arterburn L., Frye L., Hatcher P.G., et al. Mechanism of arylating quinone toxicity involving Michael adduct formation and induction of endoplasmic reticulum stress. Proc Natl Acad Sci USA 2006, 103:3604-3609.
121. Geneve J., Hayat-Bonan B., Labbe G., Degott C., Lettéron C., Fréneaux E., et al. Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther 1987, 242:1133-1137.
122. Freneaux E., Fromenty B., Berson A., Labbe G., Degott C., Lettéron P., et al. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids. J Pharmacol Exp Ther 1990, 255:529-535.
123. Zhao B., Geisslinger G., Hall I., Day R.O., Williams K.M. The effect of the enantiomers of ibuprofen and flurbiprofen on the β-oxidation of palmitate in the rat. Chirality 1992, 4:137-141.
124. Fraser J.L., Antonioli D.A., Chopra S., Wang H.H. Prevalence and nonspecificity of fatty change in the liver. Mod Pathol 1995, 8:65-70.
125. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995, 67:101-154.
126. Fromenty B., Pessayre D. Impaired mitochondrial function in microvesicular steatosis. J Hepatol 1997, 26:43-53.
127. Deschamps D., Fisch C., Fromenty B., Berson A., Degott C., Pessayre D. Inhibition by salicylic acid of the activation and thus oxidation of long-chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther 1991, 259:894-904.
128. Vianey-Liaud C., Divry N., Gregersen N., Mathieu M. The inborn errors of mitochondrial fatty acid oxidation. J Inher Metab Dis 1987, 10(Suppl. 1):159-198.
129. Danan G., Trunet P., Bernuau J., Degott C., Babany G., Pessayre D., et al. Pirprofen-induced fulminant hepatitis. Gastroenterology 1985, 89:210-213.
130. Victorino R.M.M., Silveira J.C.B., Baptista A., De Moura M.C. Jaundice associated with naproxen. Postgrad Med J 1980, 56:368.
131. Bravo J.F., Jacobson M.P., Mertens B.F. Fatty liver and pleural effusion with ibuprofen therapy. Ann Intern Med 1977, 87:200-201.
132. Dutertre J.P., Bastides F., Jonville A.P., DeMuret A., Sonneville A., Larrey D., et al. Microvesicular steatosis after ketoprofen administration. Eur J Gastroenterol Hepatol 1991, 3:953-954.
133. Fraser J.L., Antonioli D.A., Chopra S., Wang H.H. Prevalence and nonspecificity of microvesicular fatty change in the liver. Mod Pathol 1995, 8:65-70.
134. Tsutsumi S., Gotoh T., Tomisato W., Mima S., Hoshino T., Hwang H.J., et al. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Different 2004, 11:1009-1016.
135. 2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J Biol Chem 2005, 280:31059-31067.
136. Ramirez-Alcantara V., LoGuidice A., Boelsterli U.A. Protection from diclofenac-induced small intestinal injury by the JNK inhibitor SP600125 in a mouse model of NSAID-associated enteropathy. Am J Physiol (Gastrointest Liver Physiol) 2009, 297:G990-G998.
137. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002, 94:252-266.
138. Singh R., Cadeddu R.P., Froebel J., Wilk C.M., Bruns I., Zerbini L.F., et al. The non-steroidal anti-inflammatory drugs sulindac sulfide and diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway. Apoptosis 2011, 16(9):889-901.
139. Gomez-Lechon M.J., Ponsoda X., O'Connor E., Donato T., Castell J.V. Diclofenac induces apoptosis in hepatocytes. Toxicol in Vitro 2003, 17:675-680.
140. Siu W.P., Pun P.B.L., Latchoumycandane C., Boelsterli U.A. Bax-mediated mitochondrial outer membrane permeabilization (MOMP), distinct from mitochondrial permeability transition, is a key mechanism in diclofenac-induced hepatocyte injury: multiple protective roles of cyclosporin A. Toxicol Appl Pharmacol 2008, 227:451-461.
141. Cantoni L., Valaperta R., Ponsoda X., Castell J.V., Barelli D., Rizzardini M., et al. Induction of hepatic heme oxygenase-1 by diclofenac in rodents: role of oxidative stress and cytochrome P-450 activity. J Hepatol 2003, 38:776-783.
142. Fredriksson L., Herpers B., Benedetti G., Matadin Q., Puigvert J.C., de Bont H., et al. Diclofenac inhibits tumor necrosis factorα-induced nuclear factorκB activation causing synergistic hepatocyte apoptosis. Hepatology 2011, 53:2027-2041.
143. Spahn H., Näthke I., Mohri K., Zia-Amirrhosseini P., Benet L.Z. Preliminary characterization of proteins to which benoxaprofen glucuronide binds irreversibly. Pharm Res 1990, 7(Suppl.). S-257.
144. Pumford N.R., Myers T.G., Davila J.C., Highet R.J., Pohl L.R. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem Res Toxicol 1993, 6:147-150.
145. Hargus S.J., Amouzedeh H.R., Pumford N.R., Myers T.G., McCoy S.C., Pohl L.R. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 1994, 7:575-582.
146. Kretz-Rommel A., Boelsterli U.A. Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac. Radiochemical and immunochemical analysis. Mol Pharmacol 1994, 45:237-244.
147. Hargus S.J., Martin B.M., George J.W., Pohl L.R. Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 1995, 8:993-996.
148. Wade L.T., Kenna J.G., Caldwell J. Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. Chem Res Toxicol 1997, 10:546-555.
149. Myers T.G., Pumford N.R., Davila J.C., Pohl L.R. Covalent binding of diclofenac to plasma membrane proteins of the bile canaliculi in the mouse. Toxicologist 1992, 12:253.
150. Caldwell J., Fakurakzi S., Ramsay L.A., Somchit N., Goldin R.D. Benoxaprofen forms protein adducts in the bile canaliculi of female CD1 mice. Toxicol Sci 2000, 54(Suppl):46. [abstract].
151. Dong J.Q., Liu J., Smith P.C. Role of benoxaprofen and flunoxaprofen acyl glucuronides in covalent binding to rat plasma and liver proteins in vivo. Biochem Pharmacol 2005, 70:937-948.
152. Caldwell J, Somchit N, Ramsay LA, Kenna JG. Inhibition of canalicular plasma membrane dipeptidyl peptidase IV (DPP IV) is not associated with NSAID-induced hepatotoxicity in rat. Proceedings of the 5th International ISSX Meeting, Cairns, Australia 1998;13:151.
153. Wang M., Gorrell M.D., McCaughan G.W., Dickinson R.G. Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. Life Sci 2001, 68:785-797.
154. Boelsterli U.A. Reactive acyl glucuronides: possible role in small intestinal toxicity induced by nonsteroidal anti-inflammatory drugs. Toxic Subst Mech 1999, 18:83-100.
155. Boelsterli U.A. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Current Drug Metab 2002, 3:439-450.
156. Bailey M.J., Worrall S., de Jersey J., Dickinson R.G. Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system. Chem-Biol Interact 1998, 115:153-166.
157. Chiou Y.J., Tomer K.B., Smith P.C. Effect of nonenzymatic glycation of albumin and superoxide dismutase by glucuronic acid and suprofen acyl glucuronide on their functions in vitro. Chem-Biol Interact 1999, 121:141-159.
158. Aithal G.P., Ramsay L., Daly A.K., Sonchit N., Leathart J.B.S., Alexander G., et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004, 39:1430-1440.
159. Laine J.E., Auriola S., Pasanen M., Juvonen R.O. D-Isomer of gly-tyr-pro-cys-pro-his-pro peptide: a novel and sensitive in vitro trapping agent to detect reactive metabolites by electrospray mass spectrometry. Toxicol in Vitro 2011, 25:411-425.
160. De Weck A.L. Immunopathological mechanisms and clinical aspects of allergic reactions to drugs. Allergic reactions to drugs 1983, 75-133. Springer Verlag, Berlin. A.L. De Weck, H. Bungaard (Eds.).
161. Naisbitt D.J., Sanderson L.S., Meng X., Stachulski A.V., Clarke S.E., Park B.K. Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol Lett 2007, 168:45-50.
162. Franco A., Barnaba V., Natali P., Balsano C., Musca A., Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 1988, 8:449-454.
163. Harris H.W., Gill T.J. Expression of class I transplantation antigens. Transplantation 1986, 42:109-116.
164. Calmus Y., Arvieux C., Gane P., Boucher E., Nordlinger B., Rouger P., et al. Cholestasis induces major histocompatibility complex class-I expression in hepatocytes. Gastroenterology 1992, 102:1371-1377.
165. Arvieux C., Calmus Y., Gane P., Legendre C., Mariani P., Delelo R., et al. Immunogenicity of rat hepatocytes in vivo-effect of cholestasis-induced changes in major histocompatibility complex expression. J Hepatol 1993, 18:335-341.
166. Lobo-Yeo A., Senaldi G., Portmann B., Mowat A.P., Mieli-Vergani G., Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990, 12:224-232.
167. Volpes R., Vandenoord J.J., Desmet V.J. Can hepatocytes serve as activated immunomodulating cells in the immune response. J Hepatol 1992, 16:228-240.
168. Chedid A., Mendenhall C.L., Moritz T.E., French S.W., Chen T.S., Morgan T.R., et al. Cell-mediated hepatic injury in alcoholic liver disease. Gastroenterology 1993, 105:254-266.
169. Singer J.B., Lewitzky S., Leroy E., Yang F., Zhao X., Klickstein L., et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nature Genet 2010, 42:711-714.
170. Russmann S., Jetter A., Kullak-Ublik G.A. Pharmacogenetics of drug-induced liver injury. Hepatology 2010, 52:748-761.
171. Chitturi S., Farrell G.C. Identifying who is at risk of drug-induced liver injury: Is human leukocyte antigen specificity the key?. Hepatology 2011, 53:358-362.
172. Morgan R.E., Trauner M., van Staden C.J., Lee P.H., Ramachandran B., Eschenberg M., et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 2010, 118:485-500.
173. Lee J.K., Paine M.F., Brouwer K.L.R. Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes. J Pharmacol Exp Ther 2010, 334:410-418.
174. Sokol R.J., Devereaux M., Khandwala R., Obrien K. Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes. Hepatology 1993, 17:869-881.
175. Spivey J.R., Bronk S.F., Gores G.J. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Invest 1993, 92:17-24.
176. Miyoshi H., Rust C., Roberts P.J., Burgart L.J., Gores G.J. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 1999, 117:669-677.
177. Kindla J., Muller F., Mieth M., Fromm M.F., Konig J. Influence of non-steroidal anti-inflammatory drugs (NSAIDs) on OATP1B1- and OATP1B3-mediated transport. Drug Metab Disp 2011, 39:1047-1053.
178. Atchison C.R., West A.B., Balakumaran A., Hargus S.J., Pohl L.R., Daiker D.H., et al. Drug enterocyte adducts: possible causal factors for diclofenac enteropathy in rats. Gastroenterology 2000, 119:1537-1547.
179. McMillian M., Nie A.Y., Parker J.B., Leone A., Kemmerer M., Bryant S., et al. Inverse gene expression patterns for macrophage activating hepatotoxicants and peroxisome proliferators in rat liver. Biochem Pharmacol 2004, 67:2141-2165.
180. Roth R.A., Harkema J.R., Pestka J.P., Ganey P.E. Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents?. Toxicol Appl Pharmacol 1997, 147:300-311.
181. Buchweitz J.P., Ganey P.E., Bursian S.J., Roth R.A. Underlying endotoxemia augments toxic responses to chlorpromazine: Is there a relationship to drug idiosyncrasy?. J Pharmacol Exp Ther 2002, 300:460-467.
182. Deng X., Luyendyk J.P., Ganey P.E., Roth R.A. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 2009, 61:262-282.
183. Deng X., Stachlewitz R.F., Liguori M.J., Blomme E.A., Waring J.F., Luyendyk J.P., et al. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 2006, 319:1191-1199.
184. Deng X., Liguori M.J., Sparkenbaugh E.M., Waring J.F., Blomme E.A.G., Ganey P.E., et al. Gene expression profiles in livers from diclofenac-treated rats reveal intestinal bacteria-dependent and -independent pathways associated with liver injury. J Pharmacol Exp Ther 2008, 327:634-644.
185. Boelsterli U.A. Acyl glucuronides: mechanistic role in drug toxicity? (Editorial). Curr Drug Metab 2011, 12:213-214.
186. Morgan E.T. Regulation of cytochrome p450 by inflammatory mediators: Why and how?. Drug Metab Disp 2001, 29:207-212.
187. Cosgrove B.D., King B.M., Hasan M.A., Alexopoulos L.G., Farazi P.A., Hendriks B.S., et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009, 237:317-330.
188. Gitlin N. Salicylate hepatotoxicity: the potential role of hypoalbuminemia. J Clin Gastroenterol 1980, 2:281.
189. Fry S.W., Seeff L.B. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North Am 1995, 24:875-905.
190. Runyon B.A., LaBrecque D.R., Anuras S. The spectrum of liver disease in systemic lupus erythematosus: report of 33 histologically-proved cases and review of the literature. Am J Med 1980, 69:187-194.
191. Mills P.R., Sturrock R.D. Clinical associations between arthritis and liver disease. Ann Rheum Dis 1982, 41:295-307.
192. Weinblatt M.E., Tesser J., Gilliam J.H. The liver in rheumatic disease. Semin Arthritis Rheum 1982, 11:399-405.
193. Caparroz-Assef S.M., Salgueiro-Pagadigorria C.L., Bersani-Amado C.A., Bracht A., Kelmer-Bracht A.M., Ishii-Iwamoto E.L. The uncoupling effect of the nonsteroidal anti-inflammatory drug nimesulide in liver mitochondria from adjuvant-induced arthritic rats. Cell Biochem Function 2001, 19:117-124.
194. Lucena M.I., Garcia-Martin E., Andrade R.J., Martinez C., Stephens C., Ruiz J.D., et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 2010, 52:303-312.
195. Furst S.M., Gandolfi A.J. Immunologic mediation of chemical-induced hepatotoxicity. Toxicology of the liver 1998, 259-295. Taylor & Francis, Washington, DC. G.L. Plaa, W.R. Hewitt (Eds.).